CD163 and neoplasm: To further validate the stability of the model, we collected tumor tissues from 67 breast cancer patients from the clinic and examined the correlation between the staining intensity of the screened Markers: TRAF5, TLR3, RFK, FASLG, FADD, BIRC3, MAPK8 and the TME-related Markers CD11b and CD163 by immunohistochemical staining (Figure 8).